SOLID BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.98 USD | +5.15% |
|
+3.22% | +46.25% |
| 01/04 | Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label | MT |
| 01/04 | Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne | DJ |
| Sales 2024 * | 3.62M 302M | Sales 2025 * | 4.94M 412M | Capitalization | 339M 28.27B |
|---|---|---|---|---|---|
| Net income 2024 * | -95M -7.92B | Net income 2025 * | -120M -10.01B | EV / Sales 2024 * | 52.2 x |
| Net cash position 2024 * | 150M 12.5B | Net cash position 2025 * | 67.4M 5.62B | EV / Sales 2025 * | 54.9 x |
| P/E ratio 2024 * |
-3.31
x | P/E ratio 2025 * |
-3.25
x | Employees | 88 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Solid Biosciences Inc.
More recommendations
More press releases
| 1 day | +5.15% | ||
| 1 week | +3.22% | ||
| Current month | -32.58% | ||
| 1 month | -33.82% | ||
| 3 months | +12.53% | ||
| 6 months | +349.00% | ||
| Current year | +46.25% |
1 week
7.95
9.61
1 month
7.9515.05
Current year
5.2015.05
1 year
1.8115.05
3 years
1.8179.35
5 years
1.81203.70
10 years
1.81822.60
| Managers | Title | Age | Since |
|---|---|---|---|
Annie Ganot
FOU | Founder | - | 01/13/01 |
Ilan Ganot
FOU | Founder | 50 | 01/13/01 |
Alexander Cumbo
CEO | Chief Executive Officer | 53 | 29/22/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Smith
CHM | Chairman | 58 | 15/20/15 |
Martin Freed
BRD | Director/Board Member | 63 | 26/18/26 |
Raj Shah
BRD | Director/Board Member | 46 | 01/17/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 8.98 | +5.15% | 189,872 |
| 25/24/25 | 8.54 | -2.62% | 378,947 |
| 24/24/24 | 8.77 | -3.73% | 138,410 |
| 23/24/23 | 9.11 | +0.77% | 297,274 |
| 22/24/22 | 9.04 | +3.91% | 187,755 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.98
USD
Average target price
17.78
USD
Spread / Average Target
+97.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +46.25% | 339M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SLDB Stock
